Hello from Hamdi at the Academic Venture Exchange (AVX)!
Our latest listing of 75 university ventures looking for business leadership, connections, feedback, and - in some cases - funding is being hosted on our web-platform (currently in beta)!
Click here to go to AVX's Portal
Selection of Newest Opportunities
Quantum Circuits Inc. - Quantum Circuits, Inc. (QCI) is working to develop, manufacture, and sell the first practical and useful quantum computers based on superconducting devices. Along the way to building a quantum computer, QCI will commercialize the components, devices, and software that will accelerate basic research and enable the scaling of quantum computing. In Nov 2017, QCI announced a fundraising round of $18 million co-lead by Sequoia and Canaan.
Kalocyte - There is need for an artificial oxygen (O2) carrier to serve as a substitute for banked human blood in settings where stored blood is unavailable or undesirable To address this need, KaloCyte has engineered a bio-synthetic RBC substitute (ErythroMer) with physiological O2 binding, benign vascular interactions, superior biocompatibility, prolonged lyophilized stability, facile reconstitution, and scalable fabrication. Kalocyte is currently looking for a CEO to join the leadership team.
LuminiFi - WiFi today promises high throughputs and should easily support 4K video and other high bandwidth streams. However, the quality of service (QoS) is not well protected. With many devices sharing a single access point, equal sharing or simple priority schemes currently in the market are not sufficient for maintaining good QoS. Weak signal strength can make things even worse. LuminiFi's Virtual Wire technology enables the same performance isolation and QoS capability on WiFi that switched Ethernet did with original Ethernet. It is backward compatible and completely transparent, requiring no change to any hardware or software running at the endpoints (server or client).
Triursus Therapeutics - Triursus Therapeutics is a seed stage company developing monoclonal antibodies (mAbs) against two key immune surface receptors involved in immune regulation. The two first lead mAbs target key pathways that "set" the inflammatory immune thermostat. Our clinical strategy is focused on the reduction of complications after hematopoietic cell transplantation (bone marrow transplant), known as Graft vs. Host Disease (GvHD). GvHD is an orphan indication that allows for a faster pathway to market. An alternative potential indication is for inflammatory bowel disease (IBS). Triursus has recently participated in the Stanford SPARK program.
News
2017 was a very busy year for the Academic Venture Exchange! 100+ startup opportunities were hosted on AVX and shared with 200+ entrepreneurs and 30+ venture capital groups in three separate matchmaking cycles. We generated 300+ first conversations, over 30% of which became follow up discussions. From these, we have 4 matches of CEOs with start-up teams, plus 10 more in the pipeline (not counting the near misses and high-value connections made).
We also demoed our beta platform and have secured a new domain (avx.io) - to showcase the exciting range of new start-up opportunities emanating from your institutions.
Warmest regards,
Hamdi